Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 47, Issue 5, 2000, Pages 1261-1266

  Zelefsky, Michael J ^a   Hollister, Timothy ^a   Raben, Adam ^a   Matthews, Sheeba ^a   Wallner, Kent E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brachytherapy; I 125; Implantation; Prostate cancer

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PERINEUM; PRIORITY JOURNAL; PROSTATE CANCER; RATING SCALE; RECTUM HEMORRHAGE; RELAPSE; RISK; SCORING SYSTEM; TOXICITY; URETHRA STRICTURE;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; REGRESSION ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0034661749     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00550-2     Document Type: Article

References (27)

1. Zelefsky M.J., Whitmore W.F. Jr. Long term results of retropubic permanent I-125 implantation of the prostate for clinically localized prostate cancer. J Urol. 158:1997;23-30.
2. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
3. Blasko J.C., Wallner K., Grimm P.D., Ragde H. Prostate specific antigen based disease control following ultrasound guided 125-iodine implantation for stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
4. Ragde H., Elgamal A.A., Snow P.B., Brandt J., Bartolucci A.A., Nadir B.S., Korb L.J. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45 Gy external beam irradiation in the treatment of patients with clinically localized low to high Gleason grade prostate carcinoma. Cancer. 83:1998;989-1001.
5. Beyer D.C., Priestley J.B. Biochemical disease-free survival following I-125 prostate implantation. Int J Radiat Oncol Biol Phys. 37:1997;559-563.
6. Stock R.G., Stone N.N. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Sem Surg Oncol. 13:1997;454-460.
7. Consensus statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
8. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
9. Lawton C.A., Won M., Pilepich M.V., Asbell S.O., Shipley W.U., Hanks G.E., Cox J.D., Perez C.A., Sauge W.T., Doggett S.R.L., Rubin P. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate Analysis of RTOG studies 7506 and 7706 . Int J Radiat Oncol Biol Phys. 21:1991;935-936.
10. Prostate. In Manual for staging of cancer. 5th ed . 1997;203 Lippincott-Raven, Philadelphia.
11. Roy J.N., Wallner K.E., Chiu-Tsao S., et al. CT-based optimized planning for transperineal prostate implant with customized template. Int J Radiat Oncol Biol Phys. 29:1991;755-761.
12. Wallner K., Roy J., Zelefsky M.J., Fuks Z., Harrison L. Fluoroscopic visualization of the prostatic urethra to guide transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 29:1994;863-868.
13. Zelefsky M.J., Wallner K.E., Ling C.C., Raben A., Hollister T., Wolfe T., Grann A., Gaudin P., Fuks Z., Leibel S.A. Comparison of the 5-year outcome and morbidity of three dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early stage prostate cancer. J Clin Oncol. 17:1999;517-522.
14. Kaplan E.L., Meier P. Nonparametic estimation from incomplete observations. J Am Stat Assoc. 53:1958;447-457.
15. Mantel N. Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemo Reports. 50:1966;163-168.
16. Cox D.R. Regression models and life tables. J Roy Statist Soc. 34:(Series B):1972;187-220.
17. Storey M.R., Landgren R.C., Cottone J.L., et al. Transperineal 125-I implantation for treatment of clinically localized prostate cancer 5-year tumor control and morbidity . Int J Radiat Oncol Biol Phys. 43:1999;565-570.
18. Kupelian P., Katcher J., Levin H., Zippe C., Suh J., Macklis R., Klein E. External beam radiotherapy versus radical prostatectomy for clinical stage T1-T2 prostate cancer Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores . Cancer J Sci Am. 3:1997;78-87.
19. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., Tomaszewski J.E., Renshaw A.A., Kaplan I., Beard C.J., Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc. 280:1998;969-974.
20. Potters L., Cha C., Olshinsky G., Venkatraman E., Zelefsky M., Leibel S. Risk profiles to predict PSA relapse free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am. 5:1999;301-306.
21. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;247-252.
22. Pilepich M.V., Sause W.T., Shipley W.U., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic cancer A randomized comparative trial of the Radiation Therapy Oncology Group . Urology. 45:1995;616-622.
23. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
24. Stokes S.H., Real J.D., Adams P.W., Clements P.W., Wuertzer S., Kan W. Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 37:1997;337-341.
25. Gelblum D.Y., Potters L., Ashley R., Waldbaum R., Wang X.H., Leibel S. Urinary morbidity following ultrasound-guided transperineal seed implantation. Int J Radiat Oncol Biol Phys. 45:1997;59-67.
26. Zelefsky M.J., Cowen D., Fuks Z., Shike M., Burman C., Jackson A., Venkatraman E.S., Leibel S.A. Long-term tolerance of high dose three dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 85:1999;2460-2468.
27. Lee W.R., McQuellon R.P., Case L.D., deGuzman A.F., McCullough D.L. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol. 162:1999;403-406.